Therapeutic Areas

Our therapeutic areas
We create value for our therapeutic areas. In line with our efforts to develop new medicines, we promote research and innovation in our strategic therapeutic areas.
  • Allergic rhinitis
  • Allergic rhinoconjunctivitis
  • Rhinosinusitis
  • Chronic urticaria
They affect 25% of the population

They affect ~25% of the world’s population, with an increasing prevalence. Existence of unmet needs Existence of needs not covered by current treatments.

Faes Farma Solutions

We are working on new molecules in advanced preclinical phases, and new combinations in late-stage pharmaceutical development.

  • Ulcerative colitis
  • Eosinophilic oesophagitis
They affect 2.5M people

In the EU, gastrointestinal inflammatory disease chronically affects around 2.5M people, with an increasing prevalence.

Faes Farma Solutions

We work on a promising portfolio of new molecules and development of new innovative formats.

  • Vitamin D Deficiency
  • Osteoporosis
  • Autoimmune Diseases
The affect >50% of the Spanish population

>50% de la población española tiene carencia de vitamina D (c.80% en mayores de 65 años). Déficit de vitamina D asociado a osteoporosis, enf. autoinmunes, cardiovasculares, etc.

Faes Farma Solutions

We work on the research into new molecules and new formats in advanced stages of pharmaceutical development.

  • Painful muscle spasms
  • Hemorrhoid symptoms
It causes a 30% rate of work absenteeism

Musculoskeletal pain is responsible for more than 30% of work absenteeism, affecting between 13% and 47% of the population.

Faes Farma Solutions

We are working on expanding our portfolio with a novel combination, in an advanced state of pharmaceutical development.


R&D+i news
Go to News